Drug Profile
Torcetrapib
Alternative Names: CP 529414Latest Information Update: 05 Dec 2006
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Quinolines
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 02 Dec 2006 Discontinued - Phase-II for Atherosclerosis in USA (unspecified route)
- 20 Dec 2005 Data presented at the 78th Scientific Sessions of the American Heart Association (AHA-2005) have been added to the Hyperlipidaemia pharmacodynamics section
- 15 Nov 2005 Clinical data from a media release have been added to the Hyperlipidaemia pharmacodynamics section